US2012277319A1PendingUtilityA1

Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety

Assignee: STEIGERWALD ILONAPriority: Apr 29, 2011Filed: Apr 27, 2012Published: Nov 1, 2012
Est. expiryApr 29, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61P 25/20A61P 25/24A61P 25/06A61P 29/00A61P 25/22A61P 25/04A61P 17/00A61P 1/04A61P 25/00A61K 31/137A61K 9/0053
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.

Claims

exact text as granted — not AI-modified
1 . A method of treating pain in a subject suffering from depression and/or anxiety or of treating or inhibiting depression and/or of anxiety in a subject, said method comprising administering to the subject a therapeutically effective amount of tapentadol, with the proviso that the tapentadol is not administered in combination with an antiepileptic. 
     
     
         2 . The method according to  claim 1 , with the further proviso that the tapentadol is not administered in combination with an AMPA receptor antagonist. 
     
     
         3 . The method according to  claim 1 , wherein the tapentadol is administered as the only pharmacologically active ingredient. 
     
     
         4 . The method according to  claim 1 , wherein the tapentadol is administered orally. 
     
     
         5 . The method according to  claim 1 , wherein the tapentadol is administered once daily or twice daily. 
     
     
         6 . The method according to  claim 1 , wherein the tapentadol is administered at a daily dose within the range of from 25 to 600 mg. 
     
     
         7 . The method of treating pain according to  claim 1 , wherein the pain is moderate or severe. 
     
     
         8 . The method of treating pain according to  claim 1 , wherein the pain is chronic pain. 
     
     
         9 . The method according to  claim 8 , wherein the chronic pain is pain selected from the group consisting of cancer pain, chemotherapy-induced pain, upper back pain, low back pain, inflammatory pain including pain associated with rheumatic diseases, arthritic pain, ankylosing spondylitis, myofascial pain, pain associated with musculo-skeletal disorders, muscle pain, skeletal pain, joint pain, chronic pain associated with fibromyalgia, pain from strains or sprains, persistent post-operative pain, persistent posttraumatic pain, renal colic, irritable bowel syndrome-related pain, gastrointestinal pain, pelvic pain, abdominal pain, ischemic pain, angina pain, pain associated with claudication, pain accompanying myocardial infarction, vascular pain, central nervous system trauma, facial pain, migraine-related pain, headache-related pain, orofacial pain, persistent pain deriving from damaged or inflamed somatic tissue, and combinations of two or more of the foregoing. 
     
     
         10 . The method of treating pain according to  claim 1 , wherein the pain is selected from the group consisting of neuropathic pain, nociceptive pain, psychogenic pain, phantom pain and combinations of two or more of the foregoing. 
     
     
         11 . The method of treating pain according to  claim 1 , wherein the pain is neuropathic pain. 
     
     
         12 . The method according to  claim 11 , wherein the neuropathic pain is selected from the group consisting of diabetic neuralgia, monoradiculopathies, trigeminal neuralgia, post-herpetic neuralgia, persistent postoperative or posttraumatic pain, hyperalgia, allodynia, fibromyalgia, complex regional pain syndrome, pain associated with multiple sclerosis, AIDS-related neuropathy, thalamic pain, paraplegic pain caused by myelopathy, anesthesia dolorosa, low back pain, reflex sympathetic dystrophy/causalgia, cancer pain, chemotherapy-induced pain, post-thoracotomy pain, entrapment neuropathy, and peripheral neuropathy. 
     
     
         13 . The method of treating depression or anxiety according to  claim 1 , wherein the depression or anxiety is induced by pain in a subject suffering from pain. 
     
     
         14 . The method of treating depression or anxiety according to  claim 1 , wherein the depression or anxiety induces psychogenic pain. 
     
     
         15 . The method of treating depression or anxiety according to  claim 1 , wherein the depression or anxiety induces one or more symptoms selected from the group consisting of depressed affect, generalized anxiety, panic attacks, insomnia, suicidal thoughts, social inhibition, loss of energy, hopelessness, anhedonia, mood disturbances, irritability, disability, gastrointestinal disturbances, skin reactions, back pain, chest pain, headache, muscle pain and non-specific pains and aches. 
     
     
         16 . The method according to  claim 1 , wherein the tapentadol is used for
 a) the treatment of pain in a subject suffering from depression or from anxiety;   b) the treatment of depression in a subject suffering from depression or the treatment of anxiety in a subject suffering from anxiety;   c) the treatment of depression or anxiety in a subject suffering from pain;   d) the inhibition of depression or of anxiety;   e) the treatment of pain and the simultaneous treatment of depression or anxiety; or   f) the treatment of pain and simultaneous inhibition of depression or anxiety.

Join the waitlist — get patent alerts

Track US2012277319A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.